Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024
Rhea-AI Summary
Apyx Medical (NASDAQ:APYX) announced it will release its third quarter fiscal year 2024 financial results before market opening on November 8th, 2024. The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. The call will be accessible via phone (877-407-9039 for domestic, 201-689-8470 for international callers) with access code 13749764, and through a live webcast on the company's Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – APYX
On the day this news was published, APYX gained 10.00%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th.
Management will host a conference call at 8:00 a.m. Eastern Time on November 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13749764. Participants should ask for the Apyx Medical Corporation Call. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will be archived for future reference.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
FAQ
When will Apyx Medical (APYX) release Q3 2024 earnings?
How can investors join Apyx Medical's (APYX) Q3 2024 earnings call?
What time is Apyx Medical's (APYX) Q3 2024 earnings call?
